SCHEMBL4886394

SCHEMBL4886394

Cc1ccc(-c2ccc3oc(-c4cccc(C(=O)O)c4)nc3c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 11/20 0.63
KDM4E B2RXH2 4/20 0.56
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
HPGD P15428 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
POLB P06746 1/20 0.56
CASP3 P42574 1/20 0.56
SENP8 Q96LD8 1/20 0.56
SENP7 Q9BQF6 1/20 0.56
SENP6 Q9GZR1 1/20 0.56
ALDH1A1 P00352 3/20 0.55
TP53 P04637 3/20 0.55
HSD17B10 Q99714 2/20 0.55
DUSP1 P28562 2/20 0.53
MAPT P10636 2/20 0.53
NFKB1 P19838 2/20 0.53
NFKB2 Q00653 2/20 0.53
RELA Q04206 2/20 0.53
P2RY14 Q15391 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1675473 0.92 HPSE (0.66) HPSEKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1675435 0.92 HPSE (0.62) HPSEKDM4ENPC1RAB9AHPGD
SCHEMBL1675297 0.91 KDM4E (0.68) HPSEKDM4ENPC1RAB9AHPGD
SCHEMBL12171630 0.89 HPSE (0.60) HPSERAB9AMAPTHSPD1HSPE1
SCHEMBL1675394 0.87 HDAC6 (0.57) HPSEKDM4ENPC1RAB9AALDH1A1
SCHEMBL1675525 0.86 HDAC6 (0.63) HPSEKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL1675388 0.84 SMN1; SMN2 (0.68) HPSEKDM4ENPC1RAB9AHPGD
SCHEMBL1675379 0.84 HDAC6 (0.61) HPSETP53HSPD1HSPE1
SCHEMBL2242694 0.84 CASP3 (0.60) HPSEKDM4ENPC1RAB9AHPGD
SCHEMBL11564007 0.84 HPSE (0.66) HPSEKDM4ENPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases PTC THERAPEUTICS, INC. (US) 2008-10-30 US disclosed
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases PTC THERAPEUTICS, INC. (US) 2008-10-30 US disclosed
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases PTC THERAPEUTICS, INC. (US) 2008-10-30 US disclosed
EP-1812071-A2 COMPOUNDS FOR NONSENSE SUPPRESSION, USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES PTC Therapeutics, Inc. (US) 2007-08-01 EP disclosed
WO-2006044503-A2 COMPOUNDS FOR NONSENSE SUPPRESSION, USE OF THESE COMPOUNDS FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES PTC THERAPEUTICS, INC. (US) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269191-A1 Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases UPF1, NSUN2, RNMT HPSE 1899/4885KDM4E 1079/4885NPC1 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.